Market research
PRTC PureTech Health PLC
NASDAQ USD Healthcare
Latest close
As of 12 Aug 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 424M
- P/E ratio
- Not available
- Analyst target
- 46
- Dividend yield
- Not available
- Beta
- 0.79
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 424M
- P/E ratio
- Not available
- Analyst target
- 46
- Dividend yield
- Not available
- Beta
- 0.79
About
About PureTech Health PLC
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The company also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; and delivers transformative medicines for patients with psychiatric and neurological conditions. In addition, the company develops hydrogels to enable the oral administration of peptide therapeutics in preclinical development; oral therapies based on defined bacterial consortia that is in phase 3 clinical stage; and engineering hematopoietic stem cells to enable targeted therapies for patients with blood cancers. Further, it develops voice-based technology platform that detects changes in the sound of voice that are linked with health conditions, including depression, anxiety, and respiratory disease. The company was incorporated in 2015 and is based in Boston, Massachusetts.
Research context
PureTech Health PLC appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the PRTC discussion.
5 years, 6 months ago
From a valuation standpoint, the stock is 89.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 142.6.
Based on the above factors, PureTech Health plc gets an overall score of 1/5.